Non-alcoholic fatty liver disease: new therapeutic options

Abstract

The past decades have recorded sustainably high incidence of non-alcoholic fatty liver disease (NAFLD) globally. The disease is more prevalent among people with obesity and diabetes mellitus (DM), dyslipidemia and metabolic syndrome (MS) [3, 4]. NAFLD is an independent nosological unit including a range of clinical and morphological changes of the liver parenchyma: steatosis (fatty degeneration) and non-alcoholic steatohepatitis. NAFLD pharmacotherapy asks for a search of new effective methods of treatment.

Keywords

• неалкогольная жировая болезнь печени
• диагностика
• лечение
• резалют® про
• non-alcoholic fatty liver disease
• diagnosis
• treatment
• rezalut® pro